Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) is a neuroscience-focused biopharmaceutical company that completed its business combination with ARYA Sciences Acquisition Corp II, sponsored by Perceptive Advisors, in 2020. The company developed therapies targeting neurological and psychiatric disorders, with a pipeline concentrated on dopamine and GABA receptor pathways. In December 2023, Cerevel filed an 8-K disclosing that AbbVie had entered into a definitive agreement to acquire the company, representing a significant exit event for the SPAC-originated firm and its shareholders. The filing marked one of the larger biopharmaceutical SPAC acquisition outcomes of that period. Sign up at SpacDesk for full filings, timeline data, and analytics on Cerevel and the broader SPAC universe.